A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction.

ABSTRACT:

Aims

The TOPCAT trial showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF). Post-hoc, spironolactone helped participants from the Americas, but not Eastern Europe. Determining which patients with HFpEF could respond like TOPCAT's responders should help guide their care. We aimed to develop a TOPCAT Trial Score (TS) as a composite metric to identify such patients.

Methods and results

From the TOPCAT individual-level data, we calculated a TS of age, body mass index, systolic blood pressure, heart rate, creatinine, potassium, glucose, left ventricular ejection fraction, and left atrial volume for each participant as a weighted distance in multidimensional space from the theoretical perfectly average Americas participant. Logist

SUBMITTER: Belkin MN 

PROVIDER: S-EPMC8497352 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature